Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Overdose prevention
Sessions
Wednesday, 23 November
09:00
Ensuring adequate pain relief whilst reducing addiction risk: lessons learnt and the way forward
09:00
to
10:30
Main stage
Plenary session
10:50
COVID-19 implications for services and responses
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Drug treatment
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
13:20
e-/m-health interventions for substance use disorders
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Special at-risk populations and need for diversified interventions to prevent overdoses: insights from the US and Europe, on fentanyl, suicidal overdoses and deaths among teen-agers
13:20
to
14:50
Central square 4 (C4)
Structured session
15:00
Towards endemicity: A global perspective of the many variants of drug consumption rooms and service models in operation
15:00
to
16:30
Insights zone 3 (I3)
Structured session
16:50
Improving knowledge, protecting health
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Improving the health of people who use drugs
16:50
to
18:20
Networking zone 4 (N4)
Short communication session
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
15:00
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
The implementation and evaluation of “safer supply” programs in Canada as a response to an ongoing overdose crisis
15:00
to
16:30
Insights zone 4 (I4)
Structured session
16:50
Innovative approaches to tackling the drug overdoses
16:50
to
18:20
Knowledge market 1 (K1)
Oral presentation session
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
e-poster guided tour
Friday, 25 November
10:50
Mortality among people who use drugs
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
13:20
Navigating the future of supervised consumption research and intervention: European and North American experiences
13:20
to
14:50
Central square 2 (C2)
Structured session
Overdose prevention
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Presentations
Wednesday, 23 November
09:00
Keynote presentation
EFIC recommendations: When to use opioids for chronic pain and when not to
09:00
to
10:30
Main stage
Winfried Häuser
Keynote presentation
Pain and the opioid overdose crisis in the U.S.: experiences, lessons learned, and the path forward
09:00
to
10:30
Main stage
Christopher M. Jones
Keynote presentation
Changing perspectives on the use of medicines for pain
09:00
to
10:30
Main stage
Cathy Stannard
10:50
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
Oral presentation
Substance Use and Substance Use Disorders in relation to COVID-19: Qualitative Experience of Users in Jordan
10:50
to
12:20
Central square 3 (C3)
Mayyada Wazaify
Oral presentation
Overdose deaths and the COVID-19 pandemic in British Columbia, Canada
10:50
to
12:20
Central square 3 (C3)
Alexis Crabtree
Oral presentation
Changes in social work practice and support for people who use drugs during the Covid-19 pandemic – a case study of Malmö, Sweden
10:50
to
12:20
Central square 3 (C3)
Torkel Richert
Oral presentation
Drug use and attitudes toward COVID-19 vaccination in a representative sample of undergraduate students
10:50
to
12:20
Central square 3 (C3)
Stelios Stylianou
Oral presentation
Using Opioids During the COVID-19 Pandemic: experiences of people who use opioids and their healthcare providers in Nova Scotia, Canada
10:50
to
12:20
Central square 3 (C3)
Emilie Comeau
13:20
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
Oral presentation
4. Intentional overdoses and associated mental health challenges, an overlooked sub-population of overdoses
13:20
to
14:50
Central square 4 (C4)
Thomas Clausen
Oral presentation
1. Overdose prevention and treatment implications of fentanyl use in the United States
13:20
to
14:50
Central square 4 (C4)
Alexander Walley
Oral presentation
2. Fentanyl related deaths and fentanyl acute toxicity presentations at emergency Departments in Europe, 2010-2020
13:20
to
14:50
Central square 4 (C4)
Peter Heudtlass
Oral presentation
3. High drug-related death mortality in Finland – special focus on young adults and teenagers
13:20
to
14:50
Central square 4 (C4)
Prikko Kriikku
15:00
Oral presentation
1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia
15:00
to
16:30
Insights zone 3 (I3)
Marianne Jauncey
Oral presentation
2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency
15:00
to
16:30
Insights zone 3 (I3)
Jane Buxton
Oral presentation
3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs
15:00
to
16:30
Insights zone 3 (I3)
Michael Lodberg Olsen
Oral presentation
4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021
15:00
to
16:30
Insights zone 3 (I3)
Peter H. Krykant
Discussion
Discussion: synergies and challenges each region faces in relation to the model/s within which DCRs operate
15:00
to
16:30
Insights zone 3 (I3)
Jane Mounteney
16:50
Short communication
Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.
16:50
to
18:20
Networking zone 4 (N4)
Peter McCarron
Short communication
The role of a medically supervised injecting room in improving access to health and social services.
16:50
to
18:20
Networking zone 4 (N4)
Nico Clark
Short communication
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial
16:50
to
18:20
Networking zone 4 (N4)
Arne Skulberg
Oral presentation
Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project
16:50
to
18:20
Networking zone 4 (N4)
Cristiana Merendeiro
Short communication
Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network
16:50
to
18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication
Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study
16:50
to
18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication
Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study
16:50
to
18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Short communication
Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review
16:50
to
18:20
Networking zone 4 (N4)
João Pedro Ramos
Short communication
The Influence of the Synthetic Cannabinoids AMB-FUBINACA, ADB-FUBINACA, AB-CHMINACA and THJ-2201 on In Vitro Viability and Senescence of SH-SY5Y Cells and Primary Rat Hippocampal Neurons
16:50
to
18:20
Networking zone 3 (N3)
Rita Roque Bravo
Short communication
Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nationwide 2-year cross-sectional study
16:50
to
18:20
Networking zone 3 (N3)
Anne Berit Bech
Short communication
Successful microelimination of HCV among patients in the Romanian prison system
16:50
to
18:20
Networking zone 3 (N3)
Adrian Abagiu
Short communication
The synthetic cannabinoids ADB-FUBINACA and THJ-2201 decrease mitochondrial activity and ATP levels during neurodifferentiation of NG108-15 cells
16:50
to
18:20
Networking zone 3 (N3)
Rui Filipe Malheiro
Short communication
In vitro toxicity of the synthetic cannabinoids THJ-2201 and ADB-FUBINACA to human astrocytes
16:50
to
18:20
Networking zone 3 (N3)
Rafaela Silva
Short communication
Virtual Opioid User: Simulating the Effects of Counterfeit Pill Prevalence with a Control Theory Model
16:50
to
18:20
Networking zone 3 (N3)
Alexander Preiss
Short communication
Impact of the COVID-19 pandemic on drug use in the Republic of North Macedonia
16:50
to
18:20
Networking zone 3 (N3)
Sanja Prosheva
Short communication
Non-pharmacological treatment interventions in UK drug and alcohol services: an exploratory study
16:50
to
18:20
Networking zone 3 (N3)
Karen Megranahan
Short communication
Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway
16:50
to
18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Thursday, 24 November
09:00
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
15:00
Oral presentation
1. Why people who use drugs need a safe regulated supply of all drugs
15:00
to
16:30
Insights zone 4 (I4)
Natasha Touesnard,
Matthew Alexander Bonn
Oral presentation
3. A mixed methods evaluation of risk mitigation measures to address the dual public health crisis of COVID-19 and overdose
15:00
to
16:30
Insights zone 4 (I4)
Karen Urbanoski,
Bernie Pauly
Oral presentation
4. A sea of need – Safe opioid supply service provider accounts of implementing admission priorities
15:00
to
16:30
Insights zone 4 (I4)
Carol Strike
Oral presentation
5. Modeling safer supply programs: a qualitative evaluation of three safer opioid supply program models in British Columbia, Canada
15:00
to
16:30
Insights zone 4 (I4)
Andrew Ivsins,
Geoff Bardwell
Oral presentation
2. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021
15:00
to
16:30
Insights zone 4 (I4)
Allison Barker
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
16:50
Oral presentation
The limitations of decriminalization at overdose events and lessons from an evaluation in British Columbia, Canada
16:50
to
18:20
Knowledge market 1 (K1)
Alissa Greer
Oral presentation
The change in methadone dispensing requirements in England during the first wave of the COVID-19 pandemic was associated with an increase in deaths from non-prescribed methadone
16:50
to
18:20
Knowledge market 1 (K1)
Caroline Copeland
Oral presentation
Long term public health benefits and cost-effectiveness of two experimental drug consumption rooms in France
16:50
to
18:20
Knowledge market 1 (K1)
Perrine Roux
Oral presentation
The United Kingdom’s first unsanctioned safe injecting facility; a proof-of-concept evaluation
16:50
to
18:20
Knowledge market 1 (K1)
Gillian Shorter
Oral presentation
First low-threshold gender responsive residential resource for homeless people using drugs in Barcelona: descriptive evaluation of the first 6 months of activity.
16:50
to
18:20
Knowledge market 1 (K1)
Gabriela Barbaglia
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
e-poster
Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)
16:50
to
18:20
Networking zone 1 (N1)
Mohammed fathi Alafifi
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
e-poster
An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.
16:50
to
18:20
Networking zone 1 (N1)
Indhu Rammohan
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
Friday, 25 November
10:50
Oral presentation
Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK
10:50
to
12:20
Knowledge market 3 (K3)
Andrew McAuley
Oral presentation
Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation
Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.
10:50
to
12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Nicola Jones
13:20
Oral presentation
Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?
13:20
to
14:50
Knowledge market 3 (K3)
Øystein Bruun Ericson
Oral presentation
Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance
13:20
to
14:50
Knowledge market 3 (K3)
Alexander Walley
Oral presentation
The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes
13:20
to
14:50
Knowledge market 3 (K3)
Paul Dietze
Oral presentation
Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts
13:20
to
14:50
Knowledge market 3 (K3)
Nanor Minoyan
Oral presentation
3. Navigating an emergency response and collective action on the fentanyl frontlines: An ethnographic study of overdose prevention site implementation in Vancouver, Canada’s Downtown Eastside
13:20
to
14:50
Central square 2 (C2)
Ryan McNeil
Oral presentation
1. Drug consumption rooms: welfare state and social acceptance in France
13:20
to
14:50
Central square 2 (C2)
Marie Jauffret-Roustide
Oral presentation
2. Drug consumption rooms in Denmark: attitudes and experiences from local residents
13:20
to
14:50
Central square 2 (C2)
Esben Houborg
Oral presentation
4. More than overdose prevention: (Re)evaluating gender-attentive supervised consumption services
13:20
to
14:50
Central square 2 (C2)
Jade Boyd